Press enter to activate the dialog and use the tab key to navigate through the options.

Prelude Therapeutics Company Logo
  1. Top Workplaces
  2. Prelude Therapeutics

Prelude Therapeutics

Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s lead product candidates are designed to be oral, potent, and selective inhibitors of PRMT5. Prelude’s first clinical candidate, PRT543, is in Phase 1 development for advanced solid tumors and select myeloid malignancies. Prelude is also advancing PRT811, a second PRMT5 inhibitor optimized for high brain exposure, in a Phase 1 clinical trial including glioblastoma multiforme. The Company’s pipeline also includes its third clinical candidate, PRT1419, an orally available MCL1 inhibitor in Phase 1 development for patients with relapsed/refractory hematologic malignancies, and its two most advanced preclinical candidates, PRT2527, a CDK9 inhibitor, and PRT-SCA2, a SMARCA2 protein degrader.... Read more

Headquarters

Wilmington, DE

Employees

105 US Employees

Industry

Biotechnology

Recent Awards

Company Snapshots

D85_6252.jpg
D85_6725 team lunch table.jpg
Prelude_092520003.jpg
Team Photo.jpg